Søgeord (influenza) valgt.
625 emner vises.
1
Vaccine-Preventable Disease Outbreaks among Healthcare Workers: A Scoping Review
Clinical Infectious Diseases, 18.04.2024
Tilføjet 18.04.2024
Abstract Background Outbreaks of vaccine preventable diseases (VPDs) in health care workers (HCWs) can result in morbidity and mortality and cause significant disruptions to health care services, patients and visitors as well as an added burden on the health system. This scoping review is aimed to describe the epidemiology of VPD outbreaks in HCW, caused by diseases which are prevented by the ten vaccines recommended by World Health Organization (WHO) for HCWs.Methods In April 2022 CINAHL, MEDLINE, Global Health and EMBASE were searched for all articles reporting on VPD outbreaks in HCWs since the year 2000. Articles were included regardless of language and study type. Clinical and epidemiological characteristics of VPD outbreaks were described.Results Our search found 9363 articles, of which 216 met inclusion criteria. Studies describing six of the ten VPDs were found: influenza, measles, varicella, tuberculosis, pertussis and rubella. Most articles (93%) were from high- and upper middle-income countries. While most outbreaks occurred in hospitals, several influenza outbreaks were reported in long term care facilities. Based on available data, vaccination rates amongst HCWs were rarely reported.Conclusion We describe several VPD outbreaks in HCWs from 2000 to April 2022. The review emphasises the need to understand the factors influencing outbreaks in HCWs and highlight importance of vaccination amongst HCWs.
Læs mere
Tjek på PubMed
2
Detection and phylogenetic analysis of contemporary H14N2 Avian influenza A virus in domestic ducks in Southeast Asia (Cambodia)
Jurre Y. SiegersMichelle WilleSokhoun YannSongha TokSarath SinSokha CheaAlice PorcoSreyem SoursVutha ChimSamban CheaKimtuo ChhelSothyra TumSan SornMakara HakPeter ThielenVijaykrishna DhanasekaranErik A. Karlssona Virology Unit, Institute Pasteur du Cambodge, Phnom Penh, Cambodiab Centre for Pathogen Genomics, Department of Microbiology and Immunology, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australiac WHO Collaborating Centre for Reference and Research on Influenza, at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australiad Wildlife Conservation Society, Phnom Penh, Cambodiae National Animal Health and Production Research Institute, Phnom Penh, Cambodiaf Food and Agriculture Organization of the United Nations Country Office, Phnom Penh, Cambodiag Johns Hopkins University Applied Physics Laboratory, Laurel, MD, USAh School of Public Health, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, People’s Republic of Chinai HKU-Pasteur Research Pole, School of Public Health, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, People’s Republic of China
Emerg Microbes Infect, 18.04.2024
Tilføjet 18.04.2024
3
Highly pathogenic avian influenza H5N1 virus infections of dairy cattle and livestock handlers in the United States of America
Hinh LyDepartment of Veterinary & Biomedical Sciences, College of Veterinary Medicine, University of Minnesota, Twin Cities, MN, USA
Virulence, 18.04.2024
Tilføjet 18.04.2024
4
Global analysis of respiratory viral circulation and timing of epidemics in the pre-COVID-19 and COVID-19 pandemic eras, based on data from the Global Influenza Surveillance and Response System (GISRS)
Marco Del Riccio, Saverio Caini, Guglielmo Bonaccorsi, Chiara Lorini, John Paget, Koos van der Velden, Adam Meijer, Mendel Haag, Ian McGovern, Patrizio Zanobini
International Journal of Infectious Diseases, 17.04.2024
Tilføjet 17.04.2024
The emergence of the COVID-19 pandemic, caused by SARS-CoV-2, has undeniably reshaped life on a global scale. As infection rates and fatalities surged to historic proportions, initial strategies to combat the crisis revolved around non-pharmaceutical interventions (NPIs) such as the use of facemasks, physical distancing, travel bans, and lockdowns, considering the absence of available vaccines or targeted therapeutics. Characterized by a spectrum of actions spanning individual precautions to broader societal measures, NPIs aimed to curtail the rapid dissemination of the virus [1].
Læs mere
Tjek på PubMed
5
Avian ‘Bird’ Flu – undue media panic or genuine concern for pandemic potential requiring global preparedness action?
Eskild Petersen, Ziad A Memish, David S Hui, Alessandra Scagliarini, Lone Simonsen, Edgar Simulundu, Jennifer Bloodgood, Lucille Blumberg, Shui- Shan Lee, Alimuddin Zumla
International Journal of Infectious Diseases, 16.04.2024
Tilføjet 16.04.2024
6
[Articles] Global, regional, and national incidence and mortality burden of non-COVID-19 lower respiratory infections and aetiologies, 1990–2021: a systematic analysis from the Global Burden of Disease Study 2021
GBD 2021 Lower Respiratory Infections and Antimicrobial Resistance Collaborators
Lancet Infectious Diseases, 16.04.2024
Tilføjet 16.04.2024
Substantial progress has been made in reducing LRI mortality, but the burden remains high, especially in low-income and middle-income countries. During the COVID-19 pandemic, with its associated non-pharmaceutical interventions, global incident LRI cases and mortality attributable to influenza and RSV declined substantially. Expanding access to health-care services and vaccines, including S pneumoniae, H influenzae type B, and novel RSV vaccines, along with new low-cost interventions against S aureus, could mitigate the LRI burden and prevent transmission of LRI-causing pathogens.
Læs mere
Tjek på PubMed
7
Amino acids in the polymerase complex of shorebird-isolated H1N1 influenza virus impact replication and host-virus interactions in mammalian models
Yaqin BaiHui LeiWenjun SongSang-Chul ShinJiaqi WangBiying XiaoZeynep A. KoçerMin-Suk SongRobert WebsterRichard J. WebbySook-San WongMark Zanina HKU-Pasteur Research Pole, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, People's Republic of Chinab Guangzhou Medical University, Guangzhou, People’s Republic of Chinac State Key Laboratory of Respiratory Diseases, Guangzhou, People’s Republic of Chinad School of Public Health, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, People's Republic of Chinae Centre for Immunology & Infection, Hong Kong SAR, People's Republic of Chinaf Guangzhou Laboratory, Guangzhou International Bio Island, Guangzhou, People’s Republic of Chinag Korea Institute of Science and Technology, Seoul, Koreah Emerging Viral Diseases Laboratory, Izmir Biomedicine and Genome Center, Izmir, Türkiyei Department of Biomedicine and Health Technologies, Izmir International Biomedicine and Genome Institute, Izmir, Türkiyej Department of Microbiology, Chungbuk National University Medical School, Chungbuk, Koreak Department of Host-Microbe Interactions, St. Jude Children’s Research Hospital, Memphis, TN, USA
Emerg Microbes Infect, 15.04.2024
Tilføjet 15.04.2024
8
Impact of health education on promoting influenza vaccination health literacy in primary school students: a cluster randomised controlled trial protocol
Xie, W., Xiao, J., Chen, J., Huang, H., Huang, X., He, S., Xu, L.
BMJ Open, 13.04.2024
Tilføjet 13.04.2024
IntroductionInfluenza is a major public health threat, and vaccination is the most effective prevention method. However, vaccination coverage remains suboptimal. Low health literacy regarding influenza vaccination may contribute to vaccine hesitancy. This study aims to evaluate the effect of health education interventions on influenza vaccination rates and health literacy. Methods and analysisThis cluster randomised controlled trial will enrol 3036 students in grades 4–5 from 20 primary schools in Dongguan City, China. Schools will be randomised to an intervention group receiving influenza vaccination health education or a control group receiving routine health education. The primary outcome is the influenza vaccination rate. Secondary outcomes include health literacy levels, influenza diagnosis rate, influenza-like illness incidence and vaccine protection rate. Data will be collected through questionnaires, influenza surveillance and self-reports at baseline and study conclusion. Ethics and disseminationEthical approval has been sought from the Ethics Committee of the School of Public Health, Sun Yat-sen University. Findings from the study will be made accessible to both peer-reviewed journals and key stakeholders. Trial registration numberNCT06048406.
Læs mere
Tjek på PubMed
9
An infant mouse model of influenza-driven nontypeable Haemophilus influenzae colonization and acute otitis media suitable for preclinical testing of novel therapies
Katherine R. LandwehrCaitlyn M. GranlandKelly M. MartinovichNaomi M. ScottElke J. SeppanenLuke BerryDeborah StricklandAlma FulurijaPeter C. RichmondLea-Ann S. Kirkham1Wesfarmers Centre of Vaccines and Infectious Diseases, Telethon Kids Institute, Perth, Australia2School of Population Health, Curtin University, Perth, Australia3Wal-yan Respiratory Research Centre, Telethon Kids Institute, Perth, Australia4Centre for Child Health Research, University of Western Australia, Perth, Australia5Department of Paediatrics, School of Medicine, University of Western Australia, Perth, Australia6Department of Immunology, Perth Children’s Hospital, Child and Adolescent Health Service, Perth, Australia, Igor E. Brodsky
Infection and Immunity, 11.04.2024
Tilføjet 11.04.2024
10
Long-term co-circulation of multiple influenza A viruses in pigs, Guangxi, China
Chongqiang HuangLiangzheng YuYi XuJiamo HuangYibin QinXuan GuoYongfang ZengYifeng QinKang OuyangZuzhang WeiWeijian HuangAdolfo García-SastreYing Chena Laboratory of Animal Infectious Diseases and Molecular Immunology, College of Animal Science and Technology, Guangxi University, Nanning, People’s Republic of Chinab Guangxi Zhuang Autonomous Region Engineering Research Center of Veterinary Biologics, Nanning, People’s Republic of Chinac Guangxi Key Laboratory of Animal Breeding, Disease Control and Prevention, Nanning, People’s Republic of Chinad Guangxi Institute of Veterinary Medicine, Nanning, People’s Republic of Chinae Guangxi Nongken Yongxin Animal Husbandry Group Co. Ltd., Nanning, People’s Republic of Chinaf Nanning Zhufulai Animal Health Management Co. Ltd., Nanning, People’s Republic of Chinag Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USAh Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USAi Department of Medicine, Division of Infectious Diseases, Icahn School of Medicine at Mount Sinai, New York, NY, USA
Emerg Microbes Infect, 10.04.2024
Tilføjet 10.04.2024
11
Historical Comparison Between the Death Rate for Spanish Flu and Coronavirus Disease 2019 in Italy
Journal of Infectious Diseases, 10.04.2024
Tilføjet 10.04.2024
To the Editor—We read with great interest the results of the analysis by Harteloh et al [1], who concluded that the death rate in The Netherlands from the 1918–1920 Spanish flu was more than twice as high as the death rate for coronavirus disease 2019 (COVID-19) in 2020–2022 (ie, 214 vs 98 per 100 000 per year exposure). This is not surprising as the pathogen responsible for the Spanish flu pandemic (ie, influenza virus A/H1N1) was very aggressive, hit a nearly naive population with no prior immunity, and evolved at a time when healthcare and economic resources were extremely limited compared to recent times. To determine whether similar evidence could be replicated in other countries, we used statistics on the total resident population and the number of deaths from the Spanish flu in 1918–1920 [2] and from COVID-19 in 2020 [3] (ie, before the introduction of COVID-19 vaccination at the end of December 2020) in Italy.
Læs mere
Tjek på PubMed
12
Influenza C virus susceptibility to antivirals with different mechanisms of action
Anton ChesnokovAndrei A. IvashchenkoYoko MatsuzakiEmi TakashitaVasiliy P. MishinAlexandre V. IvachtchenkoLarisa V. Gubareva1Influenza Division, NCIRD, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia, USA2ChemDiv, San Diego, California, USA3Department of Infectious Diseases, Yamagata University Faculty of Medicine, Yamagata, Japan4Research Center for Influenza and Respiratory Viruses, National Institute of Infectious Diseases, Tokyo, Japan5AVISA LLC, Hallandale Beach, Florida, USA, Miguel Angel Martinez
Antimicrobial Agents And Chemotherapy, 9.04.2024
Tilføjet 9.04.2024
13
Respiratory syncytial virus vs. Influenza virus infection: mortality and morbidity comparison over 7 epidemic seasons in an elderly population
Journal of Infectious Diseases, 5.04.2024
Tilføjet 5.04.2024
Abstract Background Respiratory syncytial virus (RSV) infection is gaining interest due to the recent development of vaccines, but it is still misdiagnosed in the elderly. The primary objective was to compare all-cause mortality at day 30. Secondary objectives were to compare clinical presentation, and rates of consolidative pneumonia, hospitalization, and intensive care unit (ICU) admission.Methods Single-centre retrospective study conducted in a French university hospital during 7 epidemic seasons. All patients aged ≥75 years were included.Results 558 patients were included: 125 with RSV and 433 with Influenza. Median age was 84.8 years. RSV patients had more respiratory symptoms (wheezing, dyspnea), whereas Influenza patients had more general symptoms (fever, asthenia, myalgia). Consolidative pneumonia (28.8% vs. 17.2%; p = 0.004), hospitalization rates (83.2% vs. 70%; p = 0.003), ICU admissions (7.2% vs. 3.0%; p = 0.034) and length of stay (9 days [2-16] vs. 5 days [0-12]; p = 0.002), were higher in the RSV group. Mortality rates at day 30 were comparable (RSV 9.6%, Influenza 9.7%; p = 0.973).Conclusions This study included the largest cohort of RSV-infected patients aged over 75, documented in-depth thus far. RSV shares a comparable mortality rate with Influenza but is associated with higher rates of consolidative pneumonia, hospitalization, ICU admissions, and extended hospital stays.
Læs mere
Tjek på PubMed
14
Unveiling the role of preceding seasonal influenza in the development of bacteremic pneumococcal pneumonia in older adults before the COVID-19 pandemic in Japan
Kosuke Tamura, Reiko Shimbashi, Ayu Kasamatsu, Bin Chang, Kenji Gotoh, Yoshinari Tanabe, Koji Kuronuma, Kengo Oshima, Takaya Maruyama, Masashi Nakamatsu, Shuichi Abe, Kei Kasahara, Junichiro Nishi, Yu Arakawa, Yuki Kinjo, Motoi Suzuki, Yukihiro Akeda, Kazunori Oishi, Adult IPD Study Group
International Journal of Infectious Diseases, 5.04.2024
Tilføjet 5.04.2024
Streptococcus pneumoniae asymptomatically colonizes the nasopharynx, often causes pneumococcal disease in children and adults, and can enter the bloodstream to cause invasive pneumococcal disease (IPD). The most common presentation is bacteremic pneumonia, which accounts for approximately 60% of all adult IPD cases [1]. Adult patients with bacteremic pneumococcal pneumonia have a higher in-hospital mortality rate than those without bacteremia [2]. Therefore, understanding the diverse clinical aspects of pneumococcal infection is crucial for effective management and prevention strategies especially in adult population.
Læs mere
Tjek på PubMed
15
Incidence of Influenza-Related Medical Encounters and the Associated Healthcare Resource Use and Complications Across Adult Age Groups in The United States During the 2015-2020 Influenza Seasons
Clinical Infectious Diseases, 3.04.2024
Tilføjet 3.04.2024
Abstract Background Research on influenza burden in adults has focused on crude subgroups with cut-points at 65-years, limiting insight into how burden varies with increasing age. This study describes the incidence of influenza-related outpatient visits, emergency room (ER) visits, and hospitalizations, along with healthcare resource use and complications in the aging adult population.Methods Individuals ≥18 years of age in the United States were evaluated retrospectively in five seasonal cohorts (2015–2020 seasons) in strata of age with 5-year increments. Person-level electronic medical records linked to pharmacy and medical claims were used to ascertain patient characteristics and outcomes. Influenza-related medical encounters were identified based on diagnostic codes (ICD-10 codes J09*–J11*).Results Incidence of influenza-related outpatient visits was highest among people aged 18–34 years and declined with increasing age. For ER visits, incidence tended to be elevated for people aged 18–34 years, relatively stable from 35 through 60, and increased rapidly after 60. Hospitalization incidence remained relatively stable until about 50 years of age and then increased with age. One in three patients was diagnosed with pneumonia after hospitalization, regardless of age. Across seasons, age groups, and clinical settings, on average, 40.8% of individuals were prescribed antivirals and 17.2% antibiotics.Conclusions Incidence of influenza-related hospitalizations begins to increase around age 50 rather than the more common cut-point of 65, whereas incidence of outpatient visits was highest among younger adults. Influenza infections frequently led to antiviral and antibiotic prescriptions, underscoring the role influenza vaccination can play in combating antimicrobial resistance.
Læs mere
Tjek på PubMed
16
Immunosuppressants exert antiviral effects against influenza A(H1N1)pdm09 virus via inhibition of nucleic acid synthesis, mRNA splicing, and protein stability
Xin WangFeiyang PuXuanye YangXili FengJiayou ZhangKai DuanXuanxuan NianZhongren MaXiao-Xia MaXiao-Ming Yanga Key Laboratory of Biotechnology and Bioengineering of State Ethnic Affairs Commission, Biomedical Research Center, Northwest Minzu University, Lanzhou, Chinab School of Stomatology, Lanzhou University, Lanzhou, Chinac National Engineering Technology Research Center for Combined Vaccines, Wuhan, Chinad Wuhan Institute of Biological Products Co, Ltd, Wuhan, Chinae China National Biotech Group Company Limited, Beijing, China
Virulence, 3.04.2024
Tilføjet 3.04.2024
17
Highly pathogenic avian influenza H5N1 virus infection of companion animals
Hinh LyDepartment of Veterinary & Biomedical Sciences, College of Veterinary Medicine, University of Minnesota, Twin Cities, MN, USA
Virulence, 3.04.2024
Tilføjet 3.04.2024
18
CDC Eases Isolation Guidance for Respiratory Viruses
Journal of the American Medical Association, 2.04.2024
Tilføjet 2.04.2024
New guidance from the US Centers for Disease Control and Prevention (CDC) provides updated measures to combat respiratory viruses such as SARS-CoV-2, influenza, and respiratory syncytial virus. The recommendations come at a time when deaths and hospitalizations from COVID-19 have decreased from the peak of the pandemic and the availability of tools to fight respiratory viruses is greater than ever, the agency noted.
Læs mere
Tjek på PubMed
19
Influenza vaccination on SARS‐CoV‐2 infection risk: A subgroup analysis on geographic factor
Kuo‐Chuan Hung, Ting‐Sian Yu, Kuei‐Fen Wang, I‐Wen Chen
Journal of Medical Virology, 2.04.2024
Tilføjet 2.04.2024
20
Impact of influenza and pneumococcal vaccines on HIV persistence and immune dynamics during suppressive antiretroviral therapy
Gianella, Sara; Anderson, Christy; Chaillon, Antoine; Wells, Alan; Porrachia, Magali; Caballero, Gemma; Vargas, Milenka; Lonergan, Joseph; Woodworth, Brendon; Gaitan, Noah; Rawlings, Stephen A.; Muttera, Leticia; Harkness, Liliana; Little, Susan J.; May, Susanne; Smith, Davey
AIDS, 30.03.2024
Tilføjet 30.03.2024
Objective: :We sought to determine if standard influenza and pneumococcal vaccines can be used to stimulate HIV reservoirs during antiretroviral therapy (ART). Design: :Prospective, randomized, double-blinded, placebo-controlled, crossover trial of two clinically recommended vaccines (influenza and pneumococcal). Methods: :Persons with HIV on ART (N = 54) were enrolled in the clinical trial. Blood was collected at baseline and days 2,4,7,14 and 30 postimmunizations. Levels of cellular HIV RNA and HIV DNA were measured by ddPCR. Expression of immunological markers on T cell subsets were measured by flow cytometry. Changes in unspliced cellular HIV RNA from baseline to day 7 postinjection between each vaccine and placebo was the primary outcome. Results: :Forty-seven participants completed at least one cycle and there were no serious adverse events related to the intervention. We observed no significant differences in the change in cellular HIV RNA after either vaccine compared to placebo at any timepoint. In secondary analyses we observed a transient increase in total HIV DNA levels after influenza vaccine, as well as increased T cell activation and exhaustion on CD4+ T cells after pneumococcal vaccine. Conclusions: :Clinically recommended vaccines were safe but did not appear to stimulate the immune system strongly enough to elicit significantly noticeable HIV RNA transcription during ART. Clinicaltrials.gov identifier: NCT02707692. Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.
Læs mere
Tjek på PubMed
21
Association of viral loads of influenza A(H3N2) with age and care setting on presentation – a prospective study during the 2022/23 influenza season in Spain.
Iván Sanz-Muñoz, Javier Sánchez-Martínez, Carla Rodríguez-Crespo, Irene Arroyo-Hernantes, Marta Domínguez-Gil, Silvia Rojo-Rello, Marta Hernández, José M Eiros
International Journal of Infectious Diseases, 30.03.2024
Tilføjet 30.03.2024
Since the precise significance of viral load (VL) test for the management and treatment of patients with respiratory viruses remains unknown, it is not a commonly used tool. However, since the COVID-19 pandemic, VL evaluation has gained popularity in the scientific community and healthcare providers due to the possible application in daily clinical practice and research [1–3]. During the worst part of the pandemic, when hospitalization was overcrowded and a huge need for resources was the most important issue, the Ct value (Cycle threshold), a subrogate of the VL, was used as a criterion for discharging patients.
Læs mere
Tjek på PubMed
22
A Phase 2 Clinical Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of Different Prime-Boost Vaccination Schedules of 2013 and 2017 A(H7N9) Inactivated Influenza Virus Vaccines Administered with and without AS03 Adjuvant in Healthy US Adults
Clinical Infectious Diseases, 28.03.2024
Tilføjet 28.03.2024
Abstract Introduction A surge of human influenza A(H7N9) cases began in 2016 in China due to an antigenically distinct lineage. Data are needed about the safety and immunogenicity of 2013 and 2017 A(H7N9) inactivated influenza vaccines (IIVs) and the effects of AS03 adjuvant, prime-boost interval, and priming effects of 2013 and 2017 A(H7N9) IIVs.Methods Healthy adults (n=180), ages 19–50 years, were enrolled into this partially-blinded, randomized, multi-center Phase 2 clinical trial. Participants were randomly assigned to 1 of 6 vaccination groups evaluating homologous versus heterologous prime-boost strategies with two different boost intervals (21 versus 120 days) and two dosages (3.75 or 15 μg of hemagglutinin) administered with or without AS03 adjuvant. Reactogenicity, safety, and immunogenicity measured by hemagglutination inhibition (HAI) and neutralizing antibody titers were assessed.Results Two doses of A(H7N9) IIV were well tolerated, and no safety issues were identified. Although most participants had injection site and systemic reactogenicity, these symptoms were mostly mild to moderate in severity; injection site reactogenicity was greater in vaccination groups receiving adjuvant. Immune responses were greater after an adjuvanted second dose, and with a longer interval between prime and boost. The highest HAI GMT (95%CI) observed against the 2017 A(H7N9) strain was 133.4 (83.6, 212.6) among participants who received homologous, adjuvanted 3.75 ug+AS03/2017 doses with delayed boost interval.Conclusions Administering AS03 adjuvant with the second H7N9 IIV dose and extending the boost interval to 4 months resulted in higher peak antibody responses. These observations can broadly inform strategic approaches for pandemic preparedness. (NCT03589807)
Læs mere
Tjek på PubMed
23
Ampicillin susceptibility testing of Haemophilus influenzae in the routine clinical laboratory by the EUCAST methodology compared to broth microdilution and the presence of ftsI gene mutations
Patrick D.J. Sturm, Noud T.H. Hermans, Adri G.M. van der Zanden, Cas J.A. Peters, Tanja Schülin
Clinical Microbiology and Infection, 28.03.2024
Tilføjet 28.03.2024
To investigate the prevalence of ampicillin resistance in H. influenzae and the diagnostic accuracy of the EUCAST recommended disc diffusion method to detect the increasingly prevalent ampicillin resistance due to the presence of PBP3 alterations based on mutations in the ftsI gene.
Læs mere
Tjek på PubMed
24
Prognostic factors and prediction models for hospitalisation and all-cause mortality in adults presenting to primary care with a lower respiratory tract infection: a systematic review
Rijk, M. H., Platteel, T. N., van den Berg, T. M. C., Geersing, G.-J., Little, P., Rutten, F. H., van Smeden, M., Venekamp, R. P.
BMJ Open, 24.03.2024
Tilføjet 24.03.2024
ObjectiveTo identify and synthesise relevant existing prognostic factors (PF) and prediction models (PM) for hospitalisation and all-cause mortality within 90 days in primary care patients with acute lower respiratory tract infections (LRTI). DesignSystematic review. MethodsSystematic searches of MEDLINE, Embase and the Cochrane Library were performed. All PF and PM studies on the risk of hospitalisation or all-cause mortality within 90 days in adult primary care LRTI patients were included. The risk of bias was assessed using the Quality in Prognostic Studies tool and Prediction Model Risk Of Bias Assessment Tool tools for PF and PM studies, respectively. The results of included PF and PM studies were descriptively summarised. ResultsOf 2799 unique records identified, 16 were included: 9 PF studies, 6 PM studies and 1 combination of both. The risk of bias was judged high for all studies, mainly due to limitations in the analysis domain. Based on reported multivariable associations in PF studies, increasing age, sex, current smoking, diabetes, a history of stroke, cancer or heart failure, previous hospitalisation, influenza vaccination (negative association), current use of systemic corticosteroids, recent antibiotic use, respiratory rate ≥25/min and diagnosis of pneumonia were identified as most promising candidate predictors. One newly developed PM was externally validated (c statistic 0.74, 95% CI 0.71 to 0.78) whereas the previously hospital-derived CRB-65 was externally validated in primary care in five studies (c statistic ranging from 0.72 (95% CI 0.63 to 0.81) to 0.79 (95% CI 0.65 to 0.92)). None of the PM studies reported measures of model calibration. ConclusionsImplementation of existing models for individualised risk prediction of 90-day hospitalisation or mortality in primary care LRTI patients in everyday practice is hampered by incomplete assessment of model performance. The identified candidate predictors provide useful information for clinicians and warrant consideration when developing or updating PMs using state-of-the-art development and validation techniques. PROSPERO registration numberCRD42022341233.
Læs mere
Tjek på PubMed
25
Cross-sectional study of influenza trends and costs in Malaysia between 2016 and 2018
Sharifa Ezat Wan Puteh, Mohd Shafiq Aazmi, Muhammad Nazri Aziz, Noor ‘Adilah Kamarudin, Jamal I-Ching Sam, Ravindran Thayan, Wan Rozita Wan Mahiyuddin, Wan Noraini Wan Mohamed Noor, Adelina Cheong, Clotilde El Guerche-Séblain, Jean Khor, Eva Nabiha Zamri, Jia-Yong Lam, Zamberi Sekawi
PLoS One Infectious Diseases, 22.03.2024
Tilføjet 22.03.2024
by Sharifa Ezat Wan Puteh, Mohd Shafiq Aazmi, Muhammad Nazri Aziz, Noor ‘Adilah Kamarudin, Jamal I-Ching Sam, Ravindran Thayan, Wan Rozita Wan Mahiyuddin, Wan Noraini Wan Mohamed Noor, Adelina Cheong, Clotilde El Guerche-Séblain, Jean Khor, Eva Nabiha Zamri, Jia-Yong Lam, Zamberi Sekawi Background and objectives While influenza circulates year-round in Malaysia, research data on its incidence is scarce. Yet, this information is vital to the improvement of public health through evidence-based policies. In this cross-sectional study, we aimed to determine the trends and financial costs of influenza. Methods Data for the years 2016 through 2018 were gathered retrospectively from several sources. These were existing Ministry of Health (MOH) influenza sentinel sites data, two teaching hospitals, and two private medical institutions in the Klang Valley, Malaysia. Expert consensus determined the final estimates of burden for laboratory-confirmed influenza-like illness (ILI) and severe acute respiratory infection (SARI). Economic burden was estimated separately using secondary data supplemented by MOH casemix costing. Results Altogether, data for 11,652 cases of ILI and 5,764 cases of SARI were extracted. The influenza B subtype was found to be predominant in 2016, while influenza A was more prevalent in 2017 and 2018. The distribution timeline revealed that the highest frequency of cases occurred in March and April of all three years. The costs of influenza amounted to MYR 310.9 million over the full three-year period. Conclusions The study provides valuable insights into the dynamic landscape of influenza in Malaysia. The findings reveal a consistent year-round presence of influenza with irregular seasonal peaks, including a notable influenza A epidemic in 2017 and consistent surges in influenza B incidence during March across three years. These findings underscore the significance of continuous monitoring influenza subtypes for informed healthcare strategies as well as advocate for the integration of influenza vaccination into Malaysia’s national immunization program, enhancing overall pandemic preparedness.
Læs mere
Tjek på PubMed
26
AE-GPT: Using Large Language Models to extract adverse events from surveillance reports-A use case with influenza vaccine adverse events
Yiming Li, Jianfu Li, Jianping He, Cui Tao
PLoS One Infectious Diseases, 21.03.2024
Tilføjet 21.03.2024
by Yiming Li, Jianfu Li, Jianping He, Cui Tao Though Vaccines are instrumental in global health, mitigating infectious diseases and pandemic outbreaks, they can occasionally lead to adverse events (AEs). Recently, Large Language Models (LLMs) have shown promise in effectively identifying and cataloging AEs within clinical reports. Utilizing data from the Vaccine Adverse Event Reporting System (VAERS) from 1990 to 2016, this study particularly focuses on AEs to evaluate LLMs’ capability for AE extraction. A variety of prevalent LLMs, including GPT-2, GPT-3 variants, GPT-4, and Llama2, were evaluated using Influenza vaccine as a use case. The fine-tuned GPT 3.5 model (AE-GPT) stood out with a 0.704 averaged micro F1 score for strict match and 0.816 for relaxed match. The encouraging performance of the AE-GPT underscores LLMs’ potential in processing medical data, indicating a significant stride towards advanced AE detection, thus presumably generalizable to other AE extraction tasks.
Læs mere
Tjek på PubMed
27
Recombinant Influenza Vaccine in Adults under 65 Years of Age
New England Journal of Medicine, 21.03.2024
Tilføjet 21.03.2024
28
Stroke Risk After COVID-19 Bivalent Vaccination in US Older Adults
Journal of the American Medical Association, 19.03.2024
Tilføjet 19.03.2024
This self-controlled case series evaluates stroke risk after administration of either brand of the COVID-19 bivalent vaccine, either brand of the COVID-19 bivalent plus a high-dose or adjuvanted influenza vaccine on the same day, and a high-dose or adjuvanted influenza vaccine in Medicare beneficiaries aged 65 years or older.
Læs mere
Tjek på PubMed
29
Haemophilus influenzae endocarditis: a case report and literature review
Infection, 15.03.2024
Tilføjet 15.03.2024
Abstract Introduction Haemophilus influenzae (HI) is an exceedingly rare cause of infective endocarditis (IE). Case Presentation/Methods We present a case of a 90-year-old female diagnosed with HI-IE involving the native tricuspid valve in the absence of traditional risk factors for right-sided endocarditis. She was treated with a 5-week course of IV Ampicillin from negative cultures and suffered no complications. We also conducted a thorough literature review through PubMed and Google Scholar, which yielded a mere 15 reported cases of HI-IE. Results Fourteen of the reported HI-IE cases included epidemiological data, showing no gender predominance. The mean age of the subjects was 39.5, with the mitral valve being the most implicated (64%) and tricuspid valve involvement being rare (21%). Conclusion Native tricuspid valve IE is an uncommon entity, especially in the absence of IV drug use. Haemophilus influenzae is an extremely rare cause of IE, with a literature review showing merely 15 reported cases. This article cites the 16th case of HI-IE published in the literature.
Læs mere
Tjek på PubMed
30
Early predictors of bacterial pneumonia infection in children with congenital heart disease after cardiopulmonary bypass: a single-centre retrospective study
Wang, Q., Liu, H., Zou, L., Cun, Y., Shu, Y., Patel, N., Yu, D., Mo, X.
BMJ Open, 15.03.2024
Tilføjet 15.03.2024
ObjectivesThe objective of this study was to evaluate the early predictors of bacterial pneumonia infection in children with congenital heart disease (CHD) after cardiopulmonary bypass (CPB). DesignRetrospective study. SettingA freestanding tertiary paediatric hospital in China. ParticipantsPatients admitted to the hospital due to CHD who underwent open-heart surgery. Outcome measuresWe retrospectively reviewed and analysed data from 1622 patients with CHD after CPB from June 2018 to December 2020 at the Children’s Hospital of Nanjing Medical University. Enrolled patients were assigned to an infection group or a non-infection group according to the presence of postoperative bacterial pneumonia infection, and the differences in clinical indicators were compared. Potential predictors were analysed by multivariate logistic regression analysis and area under the curve (AUC) analysis. ResultsAmong the 376 patients (23.2%) in the infection group, the three most common bacteria were Streptococcus pneumoniae in 67 patients (17.8%), Escherichia coli in 63 patients (16.8%) and Haemophilus influenzae in 53 patients (14.1%). The infection group exhibited a lower weight (8.0 (6.0–11.5) kg vs 11.0 (7.5–14.5) kg, p
Læs mere
Tjek på PubMed
31
Analysis of viral pneumonia and risk factors associated with severity of influenza virus infection in hospitalized patients from 2012 to 2016
BMC Infectious Diseases, 13.03.2024
Tilføjet 13.03.2024
Abstract Background Influenza viruses cause pneumonia in approximately one-third of cases, and pneumonia is an important cause of death. The aim was to identify risk factors associated with severity and those that could predict the development of pneumonia. Methods This retrospective, observational study included all adult patients with confirmed influenza virus infection admitted to Son Espases University Hospital during four influenza seasons in Spain (October to May) from to 2012–2016. Results Overall, 666 patients with laboratory-confirmed influenza were included, 93 (14%) of which were severe; 73 (10.9%) were admitted to Intensive Care Unit (ICU), 39 (5.8%) died, and 185 (27.7%) developed pneumonia. Compared to less severe cases, patients with severe disease: were less vaccinated (40% vs. 28%, p = 0.021); presented with more confusion (26.9% vs. 6.8%), were more hypoxemic (Horowitz index (PaO2/FiO2) 261 vs. 280), had higher C-reactive protein (CRP) (12.3 vs. 4.0), had more coinfections (26.8% vs. 6.3%) and had more pleural effusion (14% vs. 2.6%) (last six all p
Læs mere
Tjek på PubMed
32
Nasal Delivery of Haemophilus haemolyticus Is Safe, Reduces Influenza Severity, and Prevents Development of Otitis Media in Mice
Journal of Infectious Diseases, 13.03.2024
Tilføjet 13.03.2024
Abstract Background Despite vaccination, influenza and otitis media (OM) remain leading causes of illness. We previously found that the human respiratory commensal Haemophilus haemolyticus prevents bacterial infection in vitro and that the related murine commensal Muribacter muris delays OM development in mice. The observation that M muris pretreatment reduced lung influenza titer and inflammation suggests that these bacteria could be exploited for protection against influenza/OM.Methods Safety and efficacy of intranasal H haemolyticus at 5 × 107 colony-forming units (CFU) was tested in female BALB/cARC mice using an influenza model and influenza-driven nontypeable Haemophilus influenzae (NTHi) OM model. Weight, symptoms, viral/bacterial levels, and immune responses were measured.Results Intranasal delivery of H haemolyticus was safe and reduced severity of influenza, with quicker recovery, reduced inflammation, and lower lung influenza virus titers (up to 8-fold decrease vs placebo; P ≤ .01). Haemophilus haemolyticus reduced NTHi colonization density (day 5 median NTHi CFU/mL = 1.79 × 103 in treatment group vs 4.04 × 104 in placebo, P = .041; day 7 median NTHi CFU/mL = 28.18 vs 1.03 × 104; P = .028) and prevented OM (17% OM in treatment group, 83% in placebo group; P = .015).Conclusions Haemophilus haemolyticus has potential as a live biotherapeutic for prevention or early treatment of influenza and influenza-driven NTHi OM. Additional studies will deem whether these findings translate to humans and other respiratory infections.
Læs mere
Tjek på PubMed
33
A panel of janus kinase inhibitors identified with anti-inflammatory effects protect mice from lethal influenza virus infection
Yang YuSi ChenHaonan ZhangYuanyuan DuanZhuogang LiLefang JiangWeihua CaoQun PengXulin Chen1Institute of Medical Microbiology, College of Life Science and Technology, Jinan University, Guangzhou, China2State Key Laboratory of Virology, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, China, Miguel Angel Martinez
Antimicrobial Agents And Chemotherapy, 13.03.2024
Tilføjet 13.03.2024
34
Analysis of viral pneumonia and risk factors associated with severity of influenza virus infection in hospitalized patients from 2012 to 2016
BMC Infectious Diseases, 12.03.2024
Tilføjet 12.03.2024
Abstract Background Influenza viruses cause pneumonia in approximately one-third of cases, and pneumonia is an important cause of death. The aim was to identify risk factors associated with severity and those that could predict the development of pneumonia. Methods This retrospective, observational study included all adult patients with confirmed influenza virus infection admitted to Son Espases University Hospital during four influenza seasons in Spain (October to May) from to 2012–2016. Results Overall, 666 patients with laboratory-confirmed influenza were included, 93 (14%) of which were severe; 73 (10.9%) were admitted to Intensive Care Unit (ICU), 39 (5.8%) died, and 185 (27.7%) developed pneumonia. Compared to less severe cases, patients with severe disease: were less vaccinated (40% vs. 28%, p = 0.021); presented with more confusion (26.9% vs. 6.8%), were more hypoxemic (Horowitz index (PaO2/FiO2) 261 vs. 280), had higher C-reactive protein (CRP) (12.3 vs. 4.0), had more coinfections (26.8% vs. 6.3%) and had more pleural effusion (14% vs. 2.6%) (last six all p
Læs mere
Tjek på PubMed
35
Effect of pneumococcal conjugate vaccines on viral respiratory infections: a systematic literature review
Journal of Infectious Diseases, 12.03.2024
Tilføjet 12.03.2024
Abstract Background In addition to preventing pneumococcal disease, emerging evidence indicates that pneumococcal conjugate vaccines (PCVs) might indirectly reduce viral respiratory tract infections (RTI) by affecting pneumococcal-viral interactions.Methods We performed a systematic review of interventional and observational studies published during 2000-2022 on vaccine efficacy/adjusted effectiveness (VE) and overall effect of PCV7, PCV9, PCV10, or PCV13 against viral RTI.Results Sixteen of 1671 records identified were included. Thirteen publications described effects of PCVs against viral RTIs in children. VE against influenza ranged between 41-86% (n=4), except for the 2010-2011 influenza season. In a randomized controlled trial, PCV9 displayed efficacy against any viral RTI, human seasonal coronavirus, parainfluenza, and human metapneumovirus. Data in adults were limited (n=3). PCV13 VE ranged between 4-25% against viral lower RTI, 32-35% against COVID-19 outcomes, 24-51% against human seasonal coronavirus, and 13-36% against influenza A lower RTI, with some 95%CI spanning zero. No protection was found against adenovirus or rhinovirus in children or adults.Conclusions PCVs were associated with protection against some viral RTI, with the strongest evidence for influenza in children. Limited evidence for adults was generally consistent with pediatric data. Restricting public health evaluations to confirmed pneumococcal outcomes may underestimate the full impact of PCVs.
Læs mere
Tjek på PubMed
36
Unexpected increase of severe Mycoplasma pneumoniae pneumonia in adults in Southern Switzerland
Christian Garzoni, Enos Bernasconi, Cinzia Zehnder, Simona Frigerio Malossa, Giorgio Merlani, Marco Bongiovanni
Clinical Microbiology and Infection, 9.03.2024
Tilføjet 9.03.2024
Recently, the Chinese Center for Disease Control and Prevention reported an increase in outpatient consultations and hospital admissions of children due to Mycoplasma pneumoniae pneumonia since May 2023, and RSV, adenovirus and influenza virus since October 2023 [1], occurring earlier in the season than usually expected. Similar reports have been described also in Europe and the reported symptoms are similar to those caused by already known microorganisms in circulation. [2,3].
Læs mere
Tjek på PubMed
37
Pandemic preparedness beyond COVID-19: what we know, what we do, and what we don’t
Juan M. Pericàs
Clinical Microbiology and Infection, 8.03.2024
Tilføjet 8.03.2024
Four years after the onset of COVID-19 as global public health threat that rapidly achieved pandemic proportions, it is has become commonplace both in layperson and expert circles to refer to it as a watershed. Its global reach, the attributable burden of deaths and morbidity, its enormous socioeconomic consequences, and the fact that SARS-CoV-2 has later joined the common pool of respiratory viruses considered in clinical practice, make COVID-19 special compared to its immediate precedents (e.g., SARS in 2002-2004, H1N1 influenza in 2009-2010, Ebola in 2014–2016 and 2018-2020, and Zola 2015-2016).
Læs mere
Tjek på PubMed
38
Novel influenza viral vectored vaccine against respiratory syncytial virus
Michaela Cain, Hinh Ly
Journal of Medical Virology, 6.03.2024
Tilføjet 6.03.2024
39
Preadmission course and management of severe pediatric group A streptococcal infections during the 2022–2023 outbreak: a single-center experience
Infection, 5.03.2024
Tilføjet 5.03.2024
Abstract Purpose The massive increase of infections with Group A Streptococcus (GAS) in 2022–2023 coincided in Switzerland with a change of the recommendations for the management of GAS pharyngitis. Therefore, the objective of the present study was to investigate whether the clinical manifestations and management before hospitalization for GAS infection differed in 2022–2023 compared with 2013–2022. Methods Retrospective study of GAS infections requiring hospitalization in patients below 16 years. Preadmission illness (modified McIsaac score), oral antibiotic use, and outcome in 2022–2023 were compared with 2013–2022. Time series were compared with surveillance data for respiratory viruses. Results In 2022–2023, the median modified McIsaac score was lower (2 [IQR 2–3] vs. 3 [IQR 2–4], p =
Læs mere
Tjek på PubMed
40
Protective human monoclonal antibodies target conserved sites of vulnerability on the underside of influenza virus neuraminidase
Immunity, 2.03.2024
Tilføjet 2.03.2024
Publication date: Available online 1 March 2024 Source: Immunity Author(s): Julia Lederhofer, Yaroslav Tsybovsky, Lam Nguyen, Julie E. Raab, Adrian Creanga, Tyler Stephens, Rebecca A. Gillespie, Hubza Z. Syeda, Brian E. Fisher, Michelle Skertic, Christina Yap, Andrew J. Schaub, Reda Rawi, Peter D. Kwong, Barney S. Graham, Adrian B. McDermott, Sarah F. Andrews, Neil P. King, Masaru Kanekiyo
Læs mere
Tjek på PubMed
41
Preadmission course and management of severe pediatric group A streptococcal infections during the 2022–2023 outbreak: a single-center experience
Infection, 2.03.2024
Tilføjet 2.03.2024
Abstract Purpose The massive increase of infections with Group A Streptococcus (GAS) in 2022–2023 coincided in Switzerland with a change of the recommendations for the management of GAS pharyngitis. Therefore, the objective of the present study was to investigate whether the clinical manifestations and management before hospitalization for GAS infection differed in 2022–2023 compared with 2013–2022. Methods Retrospective study of GAS infections requiring hospitalization in patients below 16 years. Preadmission illness (modified McIsaac score), oral antibiotic use, and outcome in 2022–2023 were compared with 2013–2022. Time series were compared with surveillance data for respiratory viruses. Results In 2022–2023, the median modified McIsaac score was lower (2 [IQR 2–3] vs. 3 [IQR 2–4], p =
Læs mere
Tjek på PubMed
42
Sequential Extracorporeal Therapy of Pathogen Removal Followed by Cell-Directed Extracorporeal Therapy in Streptococcal Toxic Shock Syndrome Refractory to Venoarterial Extracorporeal Membrane Oxygenation: A Case Report
Amerson, Stephen J.; Hoffman, McKenna; Abouzahr, Fadi; Ahmad, Mohammad; Sterling, Rachel K.; Gidwani, Hitesh; Sousse, Linda E.; Dellavolpe, Jeffrey D.
Critical Care Explorations, 2.03.2024
Tilføjet 2.03.2024
BACKGROUND: Streptococcal toxic shock syndrome (STSS) is a fulminant complication of predominantly invasive group A streptococcal infections. STSS is often characterized by influenza-like symptoms, including fever, chills, and myalgia that can quickly progress to sepsis with hypotension, tachycardia, tachypnea, and multiple organ failure (kidney, liver, lung, or blood). Mortality can exceed 50% depending on the severity of symptoms. CASE SUMMARY: Here, we describe a novel, multi-extracorporeal intervention strategy in a case of severe septic shock secondary to STSS. A 28-year-old woman 5 days after cesarean section developed STSS with respiratory distress, hypotension, and multiple organ failure. Despite conventional therapy with intubation, antibiotics, vasopressors, and fluid resuscitation, her condition worsened. She was placed on venoarterial extracorporeal membrane oxygenation (VA-ECMO) with subsequent initiation of pathogen hemoperfusion using the Seraph 100 blood filter, followed by immunomodulation with the selective cytopheretic device (SCD). No device-related adverse events were observed. The patient’s condition gradually stabilized with discontinuation of vasopressors after 4 days, ECMO decannulation after 6 days, evidence of renal recovery after 7 days, and extubation from mechanical ventilation after 14 days. She was transferred to conventional hemodialysis after 13 days and discontinued all kidney replacement therapy 11 days later. CONCLUSIONS: This is the first reported use of VA-ECMO, Seraph 100 hemoperfusion, and cell-directed immunomodulation with SCD. This multimodal approach to extracorporeal support represents a promising therapeutic strategy for the most refractory critical care cases. Further studies are needed to assess the safety and efficacy of this sequential approach.
Læs mere
Tjek på PubMed
43
Retraction: Properly Folded Bacterially Expressed H1N1 Hemagglutinin Globular Head and Ectodomain Vaccines Protect Ferrets against H1N1 Pandemic Influenza Virus
The PLOS ONE Editors
PLoS One Infectious Diseases, 2.03.2024
Tilføjet 2.03.2024
44
H7N6 highly pathogenic avian influenza in Mozambique, 2023
Iolanda Vieira Anahory MonjaneHernâni DjedjeEsmeralda TameleVirgínia NhabombaAlmiro Rogério TivaneZacarias Elias MassicameDercília Mudanisse AroneAmbra PastoriAlessio BortolamiIsabella MonneTimothy WomaCharles E. LamienWilliam G. Dundona Directorate of Animal Science, Central Veterinary Laboratory, Agrarian Research Institute of Mozambique, Maputo, Mozambiqueb Mozambique One Health Secretariat, National Health Institute, Maputo, Mozambiquec Ministry of Agriculture and Rural Development, National Directorate of Livestock Development, Maputo, Mozambiqued Division of Comparative Biomedical Sciences (BSBIO), Istituto Zooprofilattico Sperimentale delle Venezie (IZSVe), Padova, Italye Emergency Centre for Transboundary Animal Diseases (ECTAD), Food and Agriculture Organization (FAO), Maputo, Mozambiquef Animal Production and Health Laboratory, IAEA Laboratories, Seibersdorf, Austria
Emerg Microbes Infect, 1.03.2024
Tilføjet 1.03.2024
45
A subunit‐based influenza/SARS‐CoV‐2 Omicron combined vaccine induced potent protective immunity in BALB/c mice
Naru Zhang, Zihui Ye, Cun Li, Jie Zhou, Wei Xue, Luying Xiang, Yuewen Chen, Shuchang Chen, Rouhan Ye, Jingyin Dong, Jie Zhou, Shibo Jiang, Haijun Han
Journal of Medical Virology, 1.03.2024
Tilføjet 1.03.2024
46
The End of B/Yamagata Influenza Transmission — Transitioning from Quadrivalent Vaccines
Arnold S. Monto, Maria Zambon, Jerry P. Weir
New England Journal of Medicine, 29.02.2024
Tilføjet 29.02.2024
47
Analysis of data from two influenza surveillance hospitals in Zhejiang province, China, for the period 2018–2022
Yuda Wang, Yan Liu, Guangtao Liu, Xiuxiu Sun, Zizhe Zhang, Jianyong Shen
PLoS One Infectious Diseases, 29.02.2024
Tilføjet 29.02.2024
by Yuda Wang, Yan Liu, Guangtao Liu, Xiuxiu Sun, Zizhe Zhang, Jianyong Shen Purpose To assess the epidemiology of seasonal influenza in Huzhou City, Zhejiang Province, China, during 2018–2022 and provide insights for influenza prevention. Methods Following the National Influenza Surveillance Program, we conducted pathogen surveillance by randomly sampling throat swabs from cases with influenza-like illness (ILI) at two sentinel hospitals. Results From 2018 to 2022, a total of 3,813,471 cases were treated at two hospitals in Huzhou, China. Among them, there were 112,385 cases of Influenza-Like Illness (ILI), accounting for 2.95% of the total number of cases. A total of 11,686 ILI throat swab samples were tested for influenza viruses, with 1,602 cases testing positive for influenza virus nucleic acid, resulting in a positivity rate of 13.71%. Among the positive strains, there were 677 strains of A(H3N2) virus, 301 strains of A(H1N1) virus, 570 strains of B/Victoria virus, and 54 strains of B/Yamagata virus. The ILI percentage (ILI%) and influenza nucleic acid positivity rate showed winter-spring peaks in the years 2018, 2019, 2021, and 2022, with the peaks concentrated in January and February. Additionally, a small peak was observed in August 2022 during the summer season. No peak was observed during the winter-spring season of 2020. The highest proportion of ILI cases was observed in children aged 0–4 years, followed by school-age children aged 5–14 years. There was a positive correlation between ILI% and influenza virus nucleic acid positivity rate (r = 0.60, p < 0.05). Conclusions The influenza outbreak in Huzhou from 2020 to 2022 was to some extent influenced by the COVID-19 pandemic and public health measures. After the conclusion of the COVID-19 pandemic, the influenza outbreak in Huzhou may become more severe. Therefore, it is crucial to promptly assess the influenza outbreak trends based on the ILI% and the positivity rate of influenza virus nucleic acid tests.
Læs mere
Tjek på PubMed
48
A comparative study of apoptosis, pyroptosis, necroptosis, and PANoptosis components in mouse and human cells
Sk Mohiuddin Choudhury, Roman Sarkar, Rajendra Karki, Thirumala-Devi Kanneganti
PLoS One Infectious Diseases, 28.02.2024
Tilføjet 28.02.2024
by Sk Mohiuddin Choudhury, Roman Sarkar, Rajendra Karki, Thirumala-Devi Kanneganti Regulated cell death is a key component of the innate immune response, which provides the first line of defense against infection and homeostatic perturbations. However, cell death can also drive pathogenesis. The most well-defined cell death pathways can be categorized as nonlytic (apoptosis) and lytic (pyroptosis, necroptosis, and PANoptosis). While specific triggers are known to induce each of these cell death pathways, it is unclear whether all cell types express the cell death proteins required to activate these pathways. Here, we assessed the protein expression and compared the responses of immune and non-immune cells of human and mouse origin to canonical pyroptotic (LPS plus ATP), apoptotic (staurosporine), necroptotic (TNF-α plus z-VAD), and PANoptotic (influenza A virus infection) stimuli. When compared to fibroblasts, both mouse and human innate immune cells, macrophages, expressed higher levels of cell death proteins and activated cell death effectors more robustly, including caspase-1, gasdermins, caspase-8, and RIPKs, in response to specific stimuli. Our findings highlight the importance of considering the cell type when examining the mechanisms regulating inflammation and cell death. Improved understanding of the cell types that contain the machinery to execute different forms of cell death and their link to innate immune responses is critical to identify new strategies to target these pathways in specific cellular populations for the treatment of infectious diseases, inflammatory disorders, and cancer.
Læs mere
Tjek på PubMed
49
In vitro modelling of bacterial pneumonia: a comparative analysis of widely applied complex cell culture models
FEMS Microbiology Reviews, 27.02.2024
Tilføjet 27.02.2024
Abstract Bacterial pneumonia greatly contributes to the disease burden and mortality of lower respiratory tract infections among all age groups and risk profiles. Therefore, laboratory modelling of bacterial pneumonia remains important for elucidating the complex host-pathogen interactions and to determine drug efficacy and toxicity. In vitro cell culture enables for the creation of high-throughput, specific disease models in a tightly controlled environment. Advanced human cell culture models specifically, can bridge the research gap between the classical two-dimensional cell models and animal models. This review provides an overview of the current status of the development of complex cellular in vitro models to study bacterial pneumonia infections, with a focus on air-liquid interface models, spheroid, organoid, and lung-on-a-chip models. For the wide scale, comparative literature search, we selected six clinically highly relevant bacteria (P. aeruginosa, M. pneumoniae, H. influenzae, M. tuberculosis, S. pneumoniae, and S. aureus). We reviewed the cell lines that are commonly used, as well as trends and discrepancies in the methodology, ranging from cell infection parameters to assay read-outs. We also highlighted the importance of model validation and data transparency in guiding the research field towards more complex infection models.
Læs mere
Tjek på PubMed
50
A protectin DX (PDX) analog with in vitro activity against influenza A(H1N1) viruses
Nicolas Fortin, Mathilde Hénaut, Nathalie Goyette, René Maltais, Jean‐Yves Sancéau, André Marette, Donald Poirier, Yacine Abed, Guy Boivin
Journal of Medical Virology, 26.02.2024
Tilføjet 26.02.2024